Samsung Biologics Acquires PolyPeptide Group in 2.7 Trillion Won Deal (Update)

Samsung BioLogics is entering the peptide pharmaceuticals sector in earnest by acquiring a global peptide CDMO (Contract Development and Manufacturing Organization), a field that is drawing attention as a key area for obesity and diabetes treatments in the global pharmaceutical and biotechnology markets.

Samsung Biologics Plant 4 located in Songdo-dong, Yeonsu-gu, Incheon. Samsung Biologics

On July 20, Samsung BioLogics announced via disclosure that it had signed an acquisition agreement with PolyPeptide Group. The acquisition amount is approximately 2.7 trillion won (CHF 1.46 billion), making it the largest M&A deal in the domestic pharmaceutical and biotechnology industry.

Samsung BioLogics aims to secure 100% ownership of PolyPeptide Group through acquiring the majority stake and a public tender offer, with the goal of completing the acquisition by the end of December this year.

Peptides are ingredients used in obesity and diabetes treatments and are attracting attention alongside the growing market. With this acquisition, Samsung BioLogics will expand its existing antibody drugs, mRNA, and antibody-drug conjugates (ADC) focused business areas into the peptide segment.

This content was produced with the assistance of AI translation services.